# Liquidia Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/liquidia-technologies

- Industry: Biotechnology
- Headquarters: Morrisville, US
- Website: www.liquidia.com
- Total disclosed funding: $86M
- Latest round: Series D (Feb 2, 2018)
- Investors on record: 12

## About

Based in North Carolina, US, and founded in 2004 by CEO Roger jeffs, Liquidia Technologies Inc. operates as a biopharmaceutical company that utilizes PRINT technology that helps in developing engineered particle-based vaccines and therapeutics. In January 2024, Liquidia Technologies Inc. received USD 25 million from Healthcare Royalty Partners.  Liquidia Technologies Inc. developed a product known as Yutrepia inhalation powder, which is designed for the treatment of PAH and pulmonary arterial hypertension associated with interstitial lung disease (PH-ILD). It leverages print technology to improve lung deposition and minimize upper airway deposition, ensuring better patient outcomes. The company is also involved in the commercialization of generic Treprostinil Injection for the treatment of rare diseases, in partnership with Sandoz. In addition, the firm’s research and development developed therapies through its print technology, which allows for precise control over the size, shape, and chemical composition of drug particles.

## Funding rounds

- Series D, Feb 2, 2018, $26M — New Enterprise Associates, Canaan Partners, 5Y Capital, Xeraya Capital
- Series D, Jul 2, 2012, $3.8M — New Enterprise Associates, Canaan Partners, Bill & Melinda Gates Foundation
- Series D, Mar 3, 2011, $10M — New Enterprise Associates, Canaan Partners, Bill & Melinda Gates Foundation
- Series C, Apr 20, 2010, $5M — New Enterprise Associates, Canaan Partners, Pappas Capital, Firelake Capital Management, PPD, Inc., Morningside
- Series C, Jan 21, 2010, $13M — New Enterprise Associates, Canaan Partners, Pappas Capital, Firelake Capital Management, Morningside Private Investors
- Series C, Jul 1, 2009, $7M — New Enterprise Associates, Canaan Partners, Pappas Capital, Wakefield Group, Firelake Capital Management
- Series B, Mar 2, 2007, $16M — New Enterprise Associates, Wakefield Group, Firelake Capital Management
- Series A, May 23, 2006, $6M — N47, Wakefield Group, Firelake Capital Management

## Investors

- N47 (https://capitalatlas.ai/funds/n47) — Series A
- Wakefield Group (https://capitalatlas.ai/funds/wakefield-group) — Series A, Series B, Series C
- Firelake Capital Management (https://capitalatlas.ai/funds/firelake-capital-management) — Series A, Series B, Series C
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B, Series C, Series D
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series C, Series D
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series C
- Morningside Private Investors (https://capitalatlas.ai/funds/morningside-private-investors) — Series C
- PPD, Inc. — Series C
- Morningside (https://capitalatlas.ai/funds/morningside) — Series C
- Bill & Melinda Gates Foundation — Series D
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series D
- Xeraya Capital (https://capitalatlas.ai/funds/xeraya-capital) — Series D